Maia Biotechnology Inc
Maia Biotechnology Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions to improve patient outcomes.
Business. Maia Biotechnology Inc (MAIA.K) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Maia Biotechnology Inc (MAIA.K) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Maia Biotechnology Inc has a negative equity position of -$5.76 million and a market cap of $82.51 million, indicating a high degree of financial leverage and a speculative valuation. The company's liquidity position is characterized by a current ratio of 1.77, suggesting it can cover its short-term liabilities with its current assets, but its total liabilities of $14.48 million exceed its total assets of $8.72 million, indicating a net liability position.
The company's profitability is negative, with a net loss of $8.07 million and an operating loss of $3.95 million. Its return on equity is 1.3994, which is unusually high given the negative equity, and its return on assets is -0.9256, indicating poor asset utilization. These metrics are not directly comparable to industry medians due to the absence of industry_config data for this company.
Maia Biotechnology Inc's revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-specific financials, and its operating cash flow of -$3.59 million suggests it is not generating positive cash from operations. The absence of long-term debt indicates the company is not leveraging debt to fund operations, but this also suggests limited financial flexibility.
The company's growth trajectory is not quantified in the available data, but its negative operating and net income suggest it is not currently profitable. Analysts have assigned a mean price target of $12.13, with a median of $12.13 and a high of $14.00, indicating a potential upside from the current market price of $1.36. However, the absence of revenue history makes it difficult to assess the company's growth potential.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's dilution potential is low, and its capital structure does not show signs of recent or planned equity issuance. The absence of long-term debt and the low dilution risk suggest the company is not currently under financial pressure to raise additional capital.
Recent events and filings for Maia Biotechnology Inc are not detailed in the available data. The company's financial snapshot does not include specific events or transcripts, and the risk assessment does not flag any recent developments that would impact its financial position. The absence of detailed recent events makes it difficult to assess the company's current strategic direction or operational performance.
- Maia Biotechnology Inc is a speculative biotechnology company with a negative equity position and no long-term debt.
- The company's current ratio of 1.77 suggests it can cover its short-term liabilities, but its total liabilities exceed its total assets.
- Analysts have assigned a mean price target of $12.13, indicating a potential upside from the current market price of $1.36.
- The company's profitability is negative, with a net loss of $8.07 million and an operating loss of $3.95 million.
- Maia Biotechnology Inc has low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income +13,7% YoY; Net income −1,6% YoY.
- ▍Operating income +13,7% YoY
- ▍Net income −1,6% YoY
Operating income −123,5% YoY; Net income −225,4% YoY.
- ▍Operating income −123,5% YoY
- ▍Net income −225,4% YoY
Operating income −35,4% YoY; Net income +39,8% YoY.
- ▍Operating income −35,4% YoY
- ▍Net income +39,8% YoY
Operating income −37,4% YoY; Net income +44,0% YoY.
- ▍Operating income −37,4% YoY
- ▍Net income +44,0% YoY
Operating income -$5.0M.
- ▍Operating income -$5.0M
Operating income -$4.2M.
- ▍Operating income -$4.2M
Operating income -$3.8M.
- ▍Operating income -$3.8M
Operating income -$3.9M.
- ▍Operating income -$3.9M
Operating income −43,1% YoY; Net income +3,7% YoY.
- ▍Operating income −43,1% YoY
- ▍Net income +3,7% YoY
Operating income +16,0% YoY; Net income −17,6% YoY.
- ▍Operating income +16,0% YoY
- ▍Net income −17,6% YoY
Operating income −24,8% YoY; Net income −25,4% YoY.
- ▍Operating income −24,8% YoY
- ▍Net income −25,4% YoY
Operating income −61,0% YoY; Net income −26,1% YoY.
- ▍Operating income −61,0% YoY
- ▍Net income −26,1% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,69 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -33,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Scientific Officer · Stock Options → Common StockAcquired 400 000 @ $1,39grant · 2026-05-29
- Director, Chief Executive Officer, 10% owner · Stock Options → Common StockAcquired 800 000 @ $1,39grant · 2026-05-29
- Head of Finance · Stock Options → Common StockAcquired 60 000 @ $1,39grant · 2026-05-29
- Chief Scientific Officer · Stock Options → Common StockAcquired 400 000 @ $1,28grant · 2026-04-10
- Head of Finance · Stock Options → Common StockAcquired 30 000 @ $1,28grant · 2026-04-10
- Director, Chief Executive Officer, 10% owner · Stock Options → Common StockAcquired 800 000 @ $1,28grant · 2026-04-10
- Director · Stock Options → Common StockAcquired 27 907 @ $1,40grant · 2026-03-31
- Director · Stock Options → Common StockAcquired 27 258 @ $1,40grant · 2026-03-31
- Director · Stock Options → Common StockAcquired 33 748 @ $1,40grant · 2026-03-31
- Director · Stock Options → Common StockAcquired 28 556 @ $1,40grant · 2026-03-31
- Director · Stock Options → Common StockAcquired 27 258 @ $1,40grant · 2026-03-31
- Director · Stock Options → Common StockAcquired 33 099 @ $1,40grant · 2026-03-31
- Director · Options → Common StockAcquired 24 060 @ $1,53grant · 2025-12-31
- Director · Options → Common StockAcquired 29 216 @ $1,53grant · 2025-12-31
- Director · Options → Common StockAcquired 25 206 @ $1,53grant · 2025-12-31
- Director · Options → Common StockAcquired 29 789 @ $1,53grant · 2025-12-31
- Director · Options → Common StockAcquired 24 060 @ $1,53grant · 2025-12-31
- Director · Options → Common StockAcquired 24 633 @ $1,53grant · 2025-12-31
- Director · Stock Options → Common StockAcquired 81 699 @ $1,36purchase · 2025-12-22
- Director · Stock Options → Common StockAcquired 57 189 @ $1,36purchase · 2025-12-22
- Director · Stock Options → Common StockAcquired 40 849 @ $1,36purchase · 2025-12-22
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Maia Biotechnology Inc Market data — financials · 2026-05-28
- Maia Biotechnology Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- Chief Scientific Officer · Common StockBought 2 000 @ $1,34$3K · 2026-06-01
- Director, Chief Executive Officer, 10% owner · Common StockBought 72 700 @ $1,39$101K · 2026-06-01
- Director · Common StockBought 75 000 @ $1,34$100K · 2026-06-01
- Director · Common StockBought 57 189 @ $1,22$70K · 2025-12-22
- Director · Common StockBought 40 849 @ $1,22$50K · 2025-12-22
- Director · Common StockBought 81 699 @ $1,22$100K · 2025-12-22
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 3.08xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -34.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -20.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 3.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 12.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -4.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -95.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -942.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -230.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.66xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -43.1%Derived (calculated)
- Pre-tax income (annual): USD -22.39MSEC XBRL filing
- Total operating expenses (annual): USD 24.27MSEC XBRL filing
- Total liabilities (annual): USD 7.33MSEC XBRL filing
- Current liabilities (annual): USD 5.84MSEC XBRL filing
- Cash & equivalents (annual): USD 0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Operating income (annual): USD -24.27MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- R&D expense (annual): USD 453.75KSEC XBRL filing
- Shareholders' equity (annual): USD 2.38MSEC XBRL filing
- Current assets (annual): USD 9.7MSEC XBRL filing